群発頭痛の世界市場 - 2022年～2029年

当レポートでは、世界の群発頭痛市場について調査し、市場の概要とともに、薬剤タイプ別、タイプ別、流通チャネル別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 群発頭痛市場の調査手法と範囲

第2章 群発頭痛市場-市場の定義と概要

第3章 群発頭痛市場-エグゼクティブサマリー

• 薬剤タイプ別市場内訳
• タイプ別市場内訳
• 流通チャネル別市場内訳
• 地域別市場内訳

第4章 群発頭痛市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 群発頭痛市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 群発頭痛市場-COVID-19分析

第7章 群発頭痛市場-薬剤タイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、薬剤タイプ別
• 市場魅力指数、薬剤タイプ別
  • カルシウムチャネル遮断薬
  • コルチコステロイド
  • 局所麻酔薬
  • 炭酸リチウム
  • 麦角アルカロイド
  • その他

第8章 群発頭痛市場-タイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、タイプ別
• 市場魅力指数、タイプ別
  • 一時的
  • 慢性的

第9章 群発頭痛市場-流通チャネル別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、流通チャネル別
  • 市場魅力指数、流通チャネル別
• 院内薬局
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 小売薬局
• オンライン薬局

第10章 群発頭痛市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第11章 群発頭痛市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第12章 群発頭痛市場-企業プロファイル

• Eli Lilly and Company
• Amgen Inc.
• Grunenthal
• AbbVie Inc.
• Allergan
• Sun Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc

第13章 群発頭痛市場-DataM

Market Overview The global cluster headache market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Cluster headaches are one of the most painful headaches, as they occur in cyclical patterns of cluster periods. A cluster headache is characterised by severe pain in or around one eye on one side of the head that wakes one up in the middle of the night.

Market Dynamics

The factors influencing the global cluster headache market are the rising research and development activities and the increasing prevalence of cluster headaches.

The rising research and development activities are expected to drive the global cluster headache market in the forecast period

Cluster headache is one of the most common types of headaches. Patients experience attacks of severe unilateral pain that last 15 to 180 minutes and are in the orbital, retro-orbital, or temporal regions. Attacks can frequently happen anywhere from one to eight times per day. The disease gets its name because attacks occur in clusters that last weeks or months, with remission periods in between. These remission periods are not present in chronic cluster headaches. There are both acute and prophylactic treatment options currently available and recommended. Acute treatment with triptans can stop cluster headache attacks. There isn't much research into which triptan is the most effective. Sumatriptan or zolmitriptan, administered subcutaneously or intranasally, be effective abortive treatments. These triptans are ideal for stopping a cluster headache attack due to their quick onset of action. Intranasal administration of sumatriptan or lidocaine, oral zolmitriptan, sphenopalatine ganglion (SPG) stimulation, and subcutaneous administration of octreotide are all options for treating acute attacks. Triptans are not recommended if a patient has a history of cardiovascular disease. Years of clinical experience have shown that it should be a reason for caution rather than a complete ban. Oxygen (100 percent, 6-12 L/minute) is a tried-and-true alternative that has been shown to stop a significant number of cluster headache attacks. Moreover, on 4th June 2019, The FDA approved galcanezumab-gnlm (Emgality, Lilly) to treat cluster headaches, making it the first migraine drug.

The side effects associated with the cluster headache medication are expected to hamper the market growth

Verapamil (Calan SR, Verelan) is a calcium channel blocker frequently used to prevent cluster headaches. Other medications may interact with verapamil. In some cases, longer-term use is required to treat chronic cluster headaches. The possible side effects are constipation, nausea, fatigue, ankle swelling, and low blood pressure. Prednisone (Prednisone Intensol, Rayos) and other anti-inflammatory drugs known as corticosteroids, such as prednisone (Prednisone Intensol, Rayos), are fast-acting preventive medications that may help many people with cluster headaches. Although corticosteroids may be a good option for a few days, they are not recommended for long-term use due to serious side effects such as diabetes, hypertension, and cataracts. Hence, with the increasing side effects associated with cluster headache medication, the market is expected to be hampered.

COVID-19 Impact Analysis

COVID-19 causes headache, which is a symptom of systemic viral infections. According to recent research, 8% of COVID-19 infection patients complained of headaches. The presence of a headache does not help with COVID-19 infection diagnosis or prognosis. Infection with COVID-19 causes headache, which is likely to coexist with fever and may be dependent on it. Steroid use can cause immunosuppression and make people more susceptible to COVID-19 infection. It may be necessary to use steroids to stop a cluster attack in certain diseases (such as cluster headache). A doctor should carefully consider the use of steroids and will determine the doses and posology in each case based on treatment guidelines. To reduce the risk of infection, it is currently recommended that the number of days on steroid treatment be reduced. Hence, an increasing prevalence of headaches in patients infected with covid-19 is expected to drive market growth.

Segment Analysis

The calcium channel blockers segment is expected to dominate the market growth in the forecast period

Calcium channel blockers may be the most effective CH (Cluster Headache) prevention agents. It's possible to combine them with ergotamine or lithium. Verapamil may be the most effective calcium channel blocker, though others such as nimodipine and diltiazem have also been effective. Because of the cyclical nature of CH, which is like that of bipolar disorders, lithium has been suggested as a treatment option. It effectively treats bipolar mood disorder, another cyclic illness, and prevents CH (especially in its more chronic forms). Although responses vary (with chronic CH patients being more responsive), lithium remains the first-line treatment for CH. After the dramatic relief seen in the first week, the effect tends to fade. According to a recent report, the current therapeutic actions of available Ca2+ channel blockers are primarily limited to cardiovascular disorders. However, there is one exception: cluster headaches. As a result, high-dose verapamil is becoming a more common preventive treatment for cluster headaches, and verapamil is now the mainstay in cluster headache prevention. The dose of verapamil required for the prevention of cluster headaches varies significantly. As a result, depending on the effect and adverse events, doses ranging from 240 mg to 960 mg are recommended. Even higher doses (1200 mg) are required in a few patients. This could be due to pharmacokinetic or pharmacodynamic variability, as has been suggested in the treatment of acute migraine.

Geographical Analysis

North America region is expected to hold the largest market share in the global cluster headache market

The increasing prevalence of cluster headache and the increased healthcare infrastructure is expected to drive the market growth.

Cluster headache affects about one in every 1,000 adults in the United States. According to studies, the one-year prevalence can reach 53 per 100,000 adults. The average age of onset is between 20 and 40 years. The overall male-to-female ratio is 4.3, but chronic cluster headache has a much higher male-to-female ratio than episodic cluster headache (15 and 3.8, respectively). Cluster headaches that occur regularly are six times more common than those that occur regularly. Cluster headache has a significant socio-economic impact and associated morbidity; nearly 80% of patients say it limits their daily activities.

Moreover, on 4th June 2019, Emgality (galcanezumab-gnlm) solution for injection was approved by the US Food and Drug Administration to treat episodic cluster headache in adults. Emgality is the first FDA-approved drug to reduce the frequency of episodic cluster headache attacks, a painful and often debilitating condition.

Competitive Landscape

The global cluster headache market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are Grunenthal, AbbVie Inc., Allergan, Merck & Co., Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Eli Lilly and Company

Eli Lilly and Company

Overview: Eli Lilly and Company is an American pharmaceutical company with offices in 18 countries and headquarters in Indianapolis, Indiana. Its goods are sold in more than 125 countries. In 1876, the company was established.

Product Portfolio: Emgality is the first FDA-approved drug to reduce the frequency of episodic cluster headache attacks, a painful and often debilitating condition.

Key Development: On 4th June 2019, Emgality (galcanezumab-gnlm) solution for injection was approved by the US Food and Drug Administration for the treatment of episodic cluster headache in adults.

Why Purchase the Report?

• Visualize the composition of the global cluster headache market segmentation by drug type, by type, and distribution channel highlighting the key commercial assets and players.

• Identify commercial opportunities in global cluster headache market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of global cluster headache market- level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global cluster headache market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Table of Contents

1. Cluster Headache Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Cluster Headache Market- Market Definition and Overview

3. Cluster Headache Market- Executive Summary

• 3.1. Market Snippet By Drug Type
• 3.2. Market Snippet By Type
• 3.3. Market Snippet By Distribution Channel
• 3.4. Market Snippet By Region

4. Cluster Headache Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The rising research and development activities
  • 4.1.2. Restraints:
    • 4.1.2.1. The side effects associated with the cluster headache medication
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Cluster Headache Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Cluster Headache Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Cluster Headache Market- By Drug Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
• 7.3. Market Attractiveness Index, By Drug Type
  • 7.3.1. Calcium Channel Blockers*
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Corticosteroids
  • 7.3.3. Local Anaesthetics
  • 7.3.4. Lithium carbonate
  • 7.3.5. Ergot Alkaloids
  • 7.3.6. Others

8. Cluster Headache Market-By Type

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
• 8.3. Market Attractiveness Index, By Type
  • 8.3.1. Episodic
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Chronic

9. Cluster Headache Market- By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. Cluster Headache Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Cluster Headache Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Cluster Headache Market- Company Profiles

• 12.1. Eli Lilly and Company*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Amgen Inc.
• 12.3. Grunenthal
• 12.4. AbbVie Inc.
• 12.5. Allergan
• 12.6. Sun Pharmaceutical Industries Ltd.
• 12.7. GlaxoSmithKline plc

LIST NOT EXHAUSTIVE

13. Cluster Headache Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us